Changes of Biomarkers in Response to Training and Antioxidant Treatment

Effects of Training and Antioxidant Treatment on Circulating Markers of Oxidative Stress and Skeletal Muscle mRNA Expression

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00638560

Enrollment

Registered

2008-03-19

Start date

2008-03-31

Completion date

2008-12-31

Last updated

2010-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Type 2 Diabetes

Keywords

PGC-1alpha, PPARgamma, oxidative stress, training intervention

Brief summary

The aim of the study is to compare the effects of an intensive 4 weeks exercise training program with or without additional treatment with antioxidants. 16 volunteers are included into the study and randomized into a treatment (n=8,Vitamine E 400 IU od + vitamine C 1g twice daily) and a non-treatment (n=8, training only) group. Before and after the training program, skeletal muscle biopsies will be taken to measure PGC-1alpha and PPARgamma mRNA expression. In addition before and after the training program individuals will have the following measurements: body weight, waist circumference, body fat content (DEXA scan), euglycemic-hyperinsulinemic clamps, ergospirometer (VO2 max), routine laboratory measurements, serum malondialdehyde concentrations.

Interventions

DIETARY_SUPPLEMENTVitamin C, Vitamin E

Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily

DIETARY_SUPPLEMENTAntioxidant treatment

no treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

25 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* Must be able to swallow tablets * signed informed consent * no concommitant medication * male * age between 25 - 35 years

Exclusion criteria

* drug, tobacco or alcohol abuse * any chronic disease * any acute or chronic inflammatory disease as determined by a leucocyte count \> 7000 Gpt/l, C-reactive protein (CrP) \> 5.0 mg/dl or clinical signs of infection * systolic blood pressure (SBP) \> 140mmHg and diastolic blood pressure (DBP) was \> 85mmHg * cardiovascular or peripheral artery disease * thyroid dysfunction

Design outcomes

Primary

Measure	Time frame
PGC-1alpha mRNA expression in skeletal muscle PPARgamma mRNA expression in skeletal muscle Serum malondialdehyde concentration	after 4 weeks

Secondary

Measure	Time frame
body weight glucose infusion rate during the steady state of an euglycemic-hyperinsulinemic clamp VO2max	4 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026